Quality and purity vary significantly between suppliers
The American College of Physicians guidelines note that continued treatment is necessary to maintain weight loss, as discontinuation often leads to weight regain
The PlexusDx Precision Peptide Genetic Test can help provide pathway-level context (it does not predict your response) based on your cholesterol-related genetic variants
At 72 weeks, people taking tirzepatide lost an average of 20.2% of their body weight, compared with 13.7% for those taking semaglutide
Given that more than 7500 genetic disorders and 290,000 disease-causing mutations are cataloged in the OMIM and HGMD databases, it is not feasible to develop clinical-grade vectors for each specific mutation
In the SURMOUNT-1 trial, tirzepatide produced average weight loss of: 5 mg dose: 15.0% body weight reduction 10 mg dose: 19.5% body weight reduction 15 mg dose: 20.9% body weight reduction These results came from 72 weeks of carefully titrated, medically supervised treatment
